Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Edematous Fibrosclerotic Panniculopathy Clear all
Completed Phase 2 Interventional Results available

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

NCT01987986
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
Collagenase Clostridium Histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Santa Monica, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

NCT03632993
View directory record Official record
Conditions
Edematous Skin
Interventions
collagenase clostridium histolyticum (CCH)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coral Gables, Florida • Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

NCT03329989
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
Collagenase Clostridium Histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • Huntington Beach, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

NCT05836779
View directory record Official record
Conditions
Cellulite
Interventions
CBL-514 injection
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Encinitas, California • Encino, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

NCT05632926
View directory record Official record
Conditions
Cellulite
Interventions
40 mg CBL-514, 60 mg CBL-514, 80 mg CBL-514
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Encino, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Real World CCH Study in Adult Females With Cellulite

NCT04170296
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
11
States / cities
Encino, California • San Diego, California • Solana Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jul 23, 2026, 10:57 AM EDT
Completed No phase listed Observational

Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

NCT05249257
View directory record Official record
Conditions
Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

NCT05419505
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Antifibrinolytic Agent
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02942160
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
Collagenase Clostridium Histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT01518907
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques

NCT04580303
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite, Laxity; Skin
Interventions
collagenase clostridium histolyticum
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

NCT03428750
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
26
States / cities
Scottsdale, Arizona • Encinitas, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 23, 2026, 10:57 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530
View directory record Official record
Conditions
Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

NCT03526549
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Observation
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Glendale, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 23, 2026, 10:57 AM EDT
Completed No phase listed Observational

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

NCT03893890
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Jul 23, 2026, 10:57 AM EDT
Completed No phase listed Observational

Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)

NCT04381117
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

NCT03446781
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
25
States / cities
Glendale, Arizona • North Little Rock, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

NCT03675685
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
CCH (collagenase clostridium histolyticum)
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jul 23, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

NCT04677712
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Interventions
CCH-aaes, Compression, Cold Packs, Arnica Gel, INhance®, PDL
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 23, 2026, 10:57 AM EDT